We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Molecular Diagnostic Test for Congenital Syphilis Could Enable Immediate Treatment

By LabMedica International staff writers
Posted on 15 Sep 2023
Print article
Image: Few sensitive diagnostic tests exist to determine if a baby has developed congenital syphilis (Photo courtesy of 123RF)
Image: Few sensitive diagnostic tests exist to determine if a baby has developed congenital syphilis (Photo courtesy of 123RF)

Newborns with congenital syphilis may suffer from issues like bone damage, severe anemia, enlarged liver and spleen, jaundice, nerve issues leading to blindness or hearing loss, meningitis, or skin conditions. The severity of these health issues in the baby largely depends on whether the mother has received timely treatment for syphilis. At present, there are no sensitive diagnostic tests to confirm if a newborn has congenital syphilis. The current diagnostic approach is based on whether the mother has been treated for syphilis or if the baby shows any symptoms of the disease, along with abnormally high syphilis serology labs. As a result, doctors are forced to go through a checklist to assess if the mother has the infection and monitor the newborn for months to establish their infection status. Now, a molecular diagnostic test being developed for the detection of congenital syphilis could enable physicians to begin immediate treatment for newborns.

Researchers from UTHealth Houston (Houston, TX, USA) are working on creating a molecular diagnostic test that can quickly identify congenital syphilis, enabling immediate treatment for the affected newborns. The team is also planning a multicenter study that will examine the neurodevelopmental outcomes in babies born with the disease. This is particularly important as 60% of untreated babies born with syphilis suffer from neurodevelopmental issues.

“Our goal is to create a test for syphilis that is effective, so we can do immediate treatment,” said Irene Stafford, MD, at UTHealth Houston who is the principal investigator. “This test could be an incredible step in treating and diagnosing congenital syphilis.”

Related Links:
UTHealth Houston 

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Amoebiasis Test
ELI.H.A Amoeba
New
TRAb Immunoassay
Chorus TRAb

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more